All Blogs

Dec 27, 2023

The escalating burden of blood cancer presents a pressing global health concern, with its incidence rising steadily. This surge is attributed to various factors, including an aging population, lifestyle changes, and environmental influences. However, amidst this challenge, advancements in Blood Cancer Diagnostics D...

Dec 29, 2023

Hematopoietic progenitor kinase (HPK1) belongs to the family of Ste20 serine/threonine kinases known as mitogen-activated protein kinase kinase kinase kinase (MAP4K). It is primarily expressed in hematopoietic cells and functions as a negative regulator of T-cell receptor (TCR) and B-cell signaling, serving as an i...

Jan 01, 2024

T-cell receptor (TCR)-dependent treatment involves modified immune cells aimed at attacking particular tumor indicators. This treatment approach necessitates a systematic procedure including patient evaluation (e.g., for HLA-A*02:01 and precise tumor markers), collecting immune cells, creating the altered TCR produ...

Dec 26, 2023

ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer ImPact Biotech, a biotechnology company in its clinical stage dedicated to advancing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy for various solid tumors, announced on December 20, 2023, that the U.S....

Dec 25, 2023

Prediabetes is a significant health concern characterized by elevated blood sugar levels that fall between the normal range and the diagnostic threshold for type 2 diabetes. Often labeled as borderline diabetes, this metabolic condition is intricately linked to the global rise in obesity and poses an escalating wor...

Dec 22, 2023

In recent years, the misuse and abuse of opioids have become a growing concern worldwide, with devastating consequences for public health. While the immediate dangers of opioid overdose are well-documented, a silent and potentially lethal complication often lurks in the shadows—opioid-induced respiratory depression...

Dec 21, 2023

Integra LifeSciences to Buy Johnson & Johnson’s Acclarent and its ENT Tech On December 13, 2023, Integra LifeSciences entered into a definitive agreement to acquire Acclarent from Johnson & Johnson MedTech. Acclarent strengthens Integra's position in the ENT treatment market. Acclarent is a component of ...

Dec 20, 2023

The landscape of technology has indelibly reshaped various industries, and the healthcare sector stands as a prime beneficiary, especially evident in the profound innovation and intense development seen in the Artificial Tears Market in recent years. The advancements in nanotechnology, biotechnology, and material s...

Dec 19, 2023

Eisai Submits Marketing Authorization Application In Japan for Anticancer Agent Tasurgratinib For Biliary Tract Cancer With FGFR2 Gene Fusion Eisai Co., Ltd. has officially submitted a request for marketing authorization in Japan for tasurgratinib succinate, its internally developed tyrosine kinase inhibitor tar...

Dec 18, 2023

The development of complement inhibitors has been growing rapidly over the years, and it has proved to be one of the breakthroughs in various therapeutic areas. These inhibitors act on the dysregulated complement system, a group of proteins that forms an essential part of innate immunity. This system comes into eff...